Department of Hematology oncology, Children's hospital of Fudan university, 399 Wanyuan Road, Shanghai, China.
Clinical laboratory center, Children's hospital of Fudan University, Shanghai, China.
BMC Cancer. 2020 Mar 12;20(1):211. doi: 10.1186/s12885-020-6709-7.
Acute lymphoblastic leukemia (ALL), the most common childhood malignancy, is characterized by recurring structural chromosomal alterations and genetic alterations, whose detection is critical in diagnosis, risk stratification and prognostication. However, the genetic mechanisms that give rise to ALL remain poorly understood.
Using next-generation sequencing (NGS) in matched germline and tumor samples from 140 pediatric Chinese patients with ALL, we landscaped the gene mutations and estimated the mutation frequencies in this disease.
Our results showed that the top driver oncogenes having a mutation prevalence over 5% in childhood ALL included KRAS (8.76%), NRAS (6.4%), FLT3 (5.7%) and KMT2D (5.0%). While the most frequently mutated genes were KRAS, NRAS and FLT3 in B cell ALL (B-ALL), the most common mutations were enriched in NOTCH1 (23.1%), FBXW7 (23.1%) and PHF6 (11.5%) in T cell ALL (T-ALL). These mutant genes are involved in key molecular processes, including the Ras pathway, the Notch pathway, epigenetic modification, and cell-cycle regulation. Strikingly, more than 50% of mutations occurred in the high-hyperdiploid (HeH) ALL existed in Ras pathway, especially FLT3 (20%). We also found that the epigenetic regulator gene KMT2D, which is frequently mutated in ALL, may be involved in driving leukemia transformation, as evidenced by an in vitro functional assay.
Overall, this study provides further insights into the genetic basis of ALL and shows that Ras mutations are predominant in childhood ALL, especially in the high-hyperdiploid subtype in our research.
急性淋巴细胞白血病(ALL)是最常见的儿童恶性肿瘤,其特征是反复出现结构染色体改变和遗传改变,这些改变的检测对诊断、风险分层和预后具有重要意义。然而,导致 ALL 的遗传机制仍知之甚少。
我们使用下一代测序(NGS)技术,对 140 名中国儿童 ALL 患者的匹配种系和肿瘤样本进行了测序,绘制了基因突变图谱,并估计了该病的突变频率。
我们的结果表明,在儿童 ALL 中,突变发生率超过 5%的顶级驱动癌基因包括 KRAS(8.76%)、NRAS(6.4%)、FLT3(5.7%)和 KMT2D(5.0%)。虽然在 B 细胞 ALL(B-ALL)中最常突变的基因是 KRAS、NRAS 和 FLT3,但在 T 细胞 ALL(T-ALL)中最常见的突变是 NOTCH1(23.1%)、FBXW7(23.1%)和 PHF6(11.5%)。这些突变基因涉及关键的分子过程,包括 Ras 通路、Notch 通路、表观遗传修饰和细胞周期调控。值得注意的是,超过 50%的突变发生在 Ras 通路中存在的高超二倍体(HeH)ALL 中,尤其是 FLT3(20%)。我们还发现,ALL 中经常发生突变的表观遗传调节基因 KMT2D 可能参与驱动白血病转化,体外功能测定证实了这一点。
总之,本研究进一步深入了解了 ALL 的遗传基础,并表明 Ras 突变在儿童 ALL 中普遍存在,特别是在我们研究中的高超二倍体亚型中。